New Zealand markets open in 2 hours 4 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.43-1.72 (-6.34%)
As of 01:54PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 280.64M
Enterprise value 274.77M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)902.35
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.26

Trading information

Stock price history

Beta (5Y monthly) 2.41
52-week change 3869.64%
S&P500 52-week change 324.16%
52-week high 339.96
52-week low 32.11
50-day moving average 312.74
200-day moving average 38.44

Share statistics

Avg vol (3-month) 3819.02k
Avg vol (10-day) 3236.94k
Shares outstanding 510.34M
Implied shares outstanding 610.34M
Float 83.38M
% held by insiders 11.30%
% held by institutions 149.27%
Shares short (31 Jan 2024) 4464.74k
Short ratio (31 Jan 2024) 40.22
Short % of float (31 Jan 2024) 410.54%
Short % of shares outstanding (31 Jan 2024) 410.51%
Shares short (prior month 29 Dec 2023) 439.82k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 314 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-51.96%
Return on equity (ttm)-224.63%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -45.09M
Net income avi to common (ttm)-47.46M
Diluted EPS (ttm)-11.12
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)28.73M
Total cash per share (mrq)6.49
Total debt (mrq)22.86M
Total debt/equity (mrq)7,349.08%
Current ratio (mrq)0.99
Book value per share (mrq)0.07

Cash flow statement

Operating cash flow (ttm)-37.55M
Levered free cash flow (ttm)-20.2M